Healthcare
Mayne Pharma Group Limited(MAYNF)
Live Price
Offline$1.65
+0.00% today
1Y Change
-50.45%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $230.00M
- Revenue Growth
- +5.1%
- EPS Growth
- +46.2%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Mayne Pharma Group Limited (MAYNF) is a Healthcare stock with a market cap of $230.00M and listed on OTC. The stock last traded around $1.65 and down 50.5% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of +5.1%, EPS growth of +46.2%, a dividend yield of 0.0%. What stands out right now is revenue +5.1%, EPS +46.2%, free cash flow +114.4% with operating margin -11.2% and ROIC -6.3%. Valuation is more restrained than many high-expectation growth names at price/sales 0.6. Stock Foundry combines MAYNF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+5.1% vs +7.6% peer median
Operating Margin
Below sector median
-11.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on Feb 22, 2026 with an EPS surprise of -837.2% and a revenue surprise of -0.0%.
The operating story is still moving forward
Revenue is running at +5.1% and EPS at +46.2%, with operating margin around -11.2%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 20, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -1.8% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 22, 2026 | -837.2% | +0.0% | -5.9% | -11.6% |
2025 Aug 24, 2025 | -14403.8% | +0.0% | +0.5% | +2.0% |
2025 Feb 24, 2025 | -158.5% | +0.0% | +0.0% | +5.6% |
Benchmark Edge
MAYNF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MAYNF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MAYNF Max Drawdown
-65.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MAYNF and SPY.
Company Overview
Mayne Pharma Group Limited
Other OTC
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe and Asia. The company operates through four segments: Metrics Contract Services, International, Branded Products, and Portfolio Products. It provides oral drug delivery systems; and contract pharmaceutical development, manufacturing, and analytical services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.
- Leadership
- Aaron Gray
- IPO Date
- Mar 22, 2013
- Employees
- 450
- Street Address
- 1538 Main North Road
- Mailing
- Salisbury South, SA, 5106
- Region
- Salisbury South, SA, AU
- Reporting Currency
- USD
- Investor Line
- 61 8 8209 2666
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 8.7
- Price/Sales
- 0.6
- Price/Book
- 0.6
Growth
- Revenue
- +5.1%
- EPS
- +46.2%
- Free Cash Flow
- +114.4%
Profitability
- Gross Margin
- 54.8%
- Operating Margin
- -11.2%
- Net Margin
- -20.4%
- ROE
- -23.0%
- ROIC
- -6.3%
Balance Sheet
- Debt/Equity
- 0.13
- Current Ratio
- 1.33
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.